G0S2 is an all-trans-retinoic acid target gene

SUTISAK KITAREEWAN1, STEVEN BLUMEN1, DAVID SEKULA1, REID P. BISSONNETTE5, WILLIAM W. LAMPH5, QINGPING CUT4, ROBERT GALLAGHER4 and ETHAN DMITROVSKY1-3

Departments of 1Pharmacology and Toxicology and 2Medicine, and 3Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, NH 03755 and Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756; 4Department of Medicine and Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, NY 10467; 5Ligand Pharmaceutical, San Diego, CA 92121, USA

Received March 14, 2008; Accepted May 9, 2008

DOI: 10.3892/ijo_0000021

Abstract. All-trans-retinoic acid (RA) treatment of acute promyelocytic leukemia (APL) cases expressing the t(15;17) product, PML/RARα, is a successful example of differentiation therapy. Uncovering RA target genes is of considerable interest in APL. This study comprehensively examines in APL cells transcriptional and post-transcriptional regulation of the novel candidate RA target gene, G0S2, the G0/G1 switch gene. Reverse transcription (RT)-polymerase chain reaction (PCR) and heteronuclear PCR assays performed +/-treatment with the protein synthesis inhibitor cycloheximide (CHX) revealed G0S2 induction within 3 h of RA-treatment. Treatment with the RNA synthesis inhibitor actinomycin D did not implicate G0S2 transcript stabilization in the RA-mediated increase of G0S2 mRNA expression. Promoter elements of G0S2 were cloned into a reporter plasmid and retinoic acid receptor (RAR) co-transfection assays confirmed transcriptional activation after RA-treatment. Consistent with G0S2 being a direct RA target gene, retinoic acid response element (RARE) half-sites were found in this promoter. Mutation of these sites blocked RA-transcriptional activation of G0S2. To extend analyses to the protein expression level, a polyclonal anti-G0S2 antibody was derived and detected murine and human G0S2 species. G0S2 protein was rapidly induced in cultured NB4-S1 human APL cells and in APL transgenic mice treated with RA. An RAR pan-antagonist confirmed dependence on RARs for this induction. That these findings are clinically relevant was shown by analyses of APL cells derived directly from patients. These leukemic cells induced both a prominent increase in the cellular differentiation marker nitrotetrazolium blue (NBT) staining and marked increase in G0S2 expression. Taken together, these findings indicate G0S2 is an RA target gene. The functional role of G0S2 in retinoid response of APL warrants further study.

Introduction

All-trans-retinoic acid (RA) treatment of acute promyelocytic leukemia (APL) is a model of successful differentiation-based therapy of leukemia in patients (1,2). RA is a derivative of vitamin A and is essential for diverse biological effects, including reproduction, vision and immune function (3). RA acts as a signaling molecule that broadly modulates gene transcriptional activities, which confers both down-regulation and up-regulation of target genes (4-6). There are two families of nuclear retinoid receptors (retinoic acid receptors, RARs, and retinoid X receptors, RXRs). In the absence of the ligand RA, RARs and RXRs can heterodimerize and form a complex with inhibitory co-repressors. This complex is bound to retinoic acid response elements (RARE) of target genes, as reviewed (2,7). Upon binding to RA, the co-repressor complex is released and a stimulatory co-activator complex is recruited that modifies chromatin structure and initiates transcription of target genes that regulate growth and differentiation. Expression of the PML/RARα fusion protein is a product of the t(15;17) rearrangement found in APL also heterodimerizes with RXRs and binds to RAREs and confers transcriptional repression through dominant-negative effects. However, physiological concentrations (nM levels) of RA are not sufficient to release the co-repressor from the transcriptional complex due to its strong association with the PML/RARα fusion protein, as reviewed (2). This interrupts normal retinoid and RXR differentiation pathways and interferes with regulatory effects of PML that leads to accumulation of undifferentiated promyelocytes.

Mechanisms of RA actions that lead to APL remission are intensively studied (reviewed in refs. 2,8-10). Pharmacological dosages (μM levels) of RA trigger critical signaling events including release of the co-repressor, and recruitment of the co-activator complexes, as well as degradation of PML/RARα which results in overcoming dominant-negative effects of this fusion protein. Together, these lead to terminal differentiation of APL cells. Retinoid degradation of the fusion protein involves ubiquitin-proteasome, UBE1L, and caspase-dependent pathways (11-13).
Microarray analyses of cultured APL cells revealed RA activates gene expression including G0S2 in RA-sensitive, but not RA-resistant APL cells (14). One of the most prominently induced species is G0S2, a member of the Gp/Gq, switch gene family, which was first reported as markedly induced in mono-nuclear hematopoietic cells following treatment with the lectin concanavalin A and the inhibitor of protein synthesis, cycloheximide (CHX) (15,16). Agonists of the peroxisome-proliferator-activated receptors (PPARs) were reported to induce G0S2 expression (17). Because its mRNA induced expression coincided with cell cycle progression from G0 to G1 by lectin- or CHX-treatment of lymphocytes (15,16,18,19) and induction during differentiation of adipocytes by PPAR ligands (17), cell cycle regulation and differentiation roles were proposed for G0S2.

The mechanistic basis for RA-mediated differentiation of APL is under study, as reviewed (2). Yet, the identity of involved target genes remains to be discerned. Findings from our team and others (14-20), led us to hypothesize that G0S2 is a target gene for RA regulation. This study was undertaken to explore this hypothesis and provide evidence for G0S2 as a direct retinoid target gene in APL.

Materials and methods

Chemicals and antibodies. RA, CHX, actinomycin D and dimethyl sulfoxide (DMSO) were each purchased (Sigma, St. Louis, MO), as were G418, penicillin/streptomycin, L-glutamine (Mediatech, Herndon, VA), fetal bovine serum (FBS) (Gemini Bio-Products, Calabasas, CA), anti-actin, anti-RARβ, and anti-RARα antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). ECL Plus chemiluminescent immunoblotting detection reagents were obtained (GE Healthcare UK Limited, Buckinghamshire, UK) as was an anti-myc antibody (Covance, Berkeley, CA). The protease arrest protease inhibitor mixture was purchased (GenoTechnology, St. Louis, MO), as were SYBR Safe DNA stain, advanced RPM-1640, advanced DMEM, α-MEM and LHC-8 media (Invitrogen, Carlsbad, CA).

Cell culture. NB4-S1 and NB4-R1, derived from parental NB4 cells, are clonal APL cell lines that are either sensitive or resistant to RA, respectively (21). Parental NB4 cells were derived from a patient with APL; these leukemic cells contain the t(15;17) chromosomal translocation that encodes the PML/RARα fusion protein (22). Cell lines were cultured in their respective media containing penicillin (100 U/ml) and streptomycin (100 μg/ml) in 5% CO2 and in a humidified incubator at 37°C. NB4-S1 and NB4-R1 cells were cultured in advanced RPM-1640 medium supplemented with 2% FBS and 4 mM L-glutamine. Chinese hamster ovary (CHO) cells were cultured in α-MEM medium supplemented with 5% FBS and 2 mM L-glutamine. The green monkey kidney COS-1 cell line was cultured in advanced DMEM medium supplemented with 2% FBS and 4 mM L-glutamine. The immortalized human bronchial epithelial cell line BEAS-2B was cultured in LHC-9 serum-free medium, as previously described (12).

G0S2 RT-PCR assays. Total cellular RNA was isolated from NB4-S1 cells cultured at 2x10⁵ cells/ml in the presence of RA (1 μM) for 0, 3, 6, 12, 24, and 48 h using TRI-reagent according to the manufacturer's protocol (Molecular Research Center, Inc., Cincinnati, OH). CHX (10 μg/ml) was added 30 min before RA-treatment. Complementary DNAs (cDNAs) were synthesized using SuperScriptII RNase H reverse transcriptase (RT) according to the manufacturer's recommended procedures (Invitrogen). G0S2 mRNA was amplified from cDNA with the forward primer 5'-GGGAAAGATGGTGAAGCTGTA-3' and reverse primer 5'-CTGGTCTCACCAGTTCCTA-3' using Taq DNA polymerase (Invitrogen). Optimized polymerase chain reaction (PCR) assay conditions were used to amplify G0S2 cDNA and the 269 base pair (bp) PCR product was resolved on a 1% agarose gel with SYBR Safe DNA staining. As a control, human β-actin mRNA was amplified from the same cDNA using the forward primer 5'-GGGAAGGGCTTAAAGTGC-3' and reverse primer 5'-AAGGAAGGGCTTAAAGTGC-3' to produce a PCR fragment of 183 bp. G0S2 mRNA stability was investigated by treating 5x10⁵ NB4-S1 cells/ml with RA (1 μM) for 15.5 h before addition of 2 μg actinomycin D/ml. Total RNA was independently harvested at 0, 1, 2, 4, 6 and 8 h after actinomycin D treatment. Stability of heteronuclear G0S2 RNA was investigated using RT-PCR assays and the forward primer 5'-CTATGAGCCCTCCCCAAGAT-3' and reverse primer 5'-TGCACACAGTCCCATCGAG-3', generating a 264-bp product.

Full-length G0S2 mRNA was isolated from NB4-S1 cells, reverse transcribed and amplified using the forward primer 5'-AGATGGAAACGCTGCCA-3' and reverse primer 5'-CTGGTCTCACCAGTTCCTA-3', and cloned into the pcMV-Myc vector. This 330-bp PCR product was cloned into the pCRII-TOPO vector (Invitrogen) and subsequently cleaved with EcoRI restriction endonuclease. The EcoRI restricted fragment was then cloned in the sense orientation into the EcoRI site of the pcMV-Myc vector (Clonetech, Mountain View, CA). Restriction endonuclease digestions and sequence analyses were performed to confirm cloning of the desired species.

G0S2 reporter assays. The 2563-bp G0S2 promoter sequence was amplified with a Pfx DNA polymerase (Invitrogen) from genomic DNA isolated from NB4-S1 cells, using the forward primer 5'-CTAGAGGCAGCAGTCTTCTT-3' and reverse primer 5'-GGGCTTCCAGCACAAAGAAA-3'. This amplified product was cloned into the TOPO TA cloning vector (Invitrogen), which was excised with KpnI and Xhol restriction endonucleases and then cloned into the Kpnl and Xhol sites of the pGL3-basic luciferase reporter plasmid (Promega, Madison, WI). The pGL3-G0S2-luciferase activity was measured using transient co-transfection assays. Briefly, each 6-well plate was seeded with 3x10⁴ CHO cells/well overnight before transfection. The G0S2 reporter construct (0.25 μg/μl), RAR expression vectors (0.15 μg/μl) and β-galactosidase expression vector (0.25 μg/μl) were respectively transfected into CHO cells using Effectene transfection reagent (Qiagen, Valencia, CA) as per the manufacturer's instructions. Following overnight transfection, cells were washed once with phosphate buffered saline (PBS) and fresh culture medium was added supplemented with RA (10 μM) or vehicle (DMSO). Transfectants were cultured for 24 h before harvesting for luciferase
and β-galactosidase activity assays. β-galactosidase activity, however, was not used to normalize for luciferase activity as RA-treatment of transfectants was observed to suppress β-galactosidase activity.

Identification of RAREs. RAREs in the G0S2 promoter were identified by a unidirectional nested deletion of the G0S2 promoter sequence cloned into the pGL3-G0S2-luciferase plasmid. The unidirectional nested deletion of the G0S2 promoter was performed, as previously described (23). Briefly, the pGL3-G0S2-luciferase vector was digested with KpnI and SpeI restriction endonucleases and an exonuclease III was then used to restrict the 3'-overhanging SpeI site. A series of truncated G0S2 promoter reporter vectors was generated by terminating exonuclease III activity at various times before religation to the reporter plasmid. These serially-deleted G0S2 promoter constructs were examined for luciferase activities via transient co-transfection assays with RARα in CHO cells without and with RA (1 μM), as described above.

G0S2 RARE mutations. Putative G0S2 RARE half-sites were mutated to a non-functional RARE consensus sequence using two-step PCR assays (24) with the upstream primer 5'-AGTG CAGGTGCCAGAACATTT-3' and downstream reverse primer 5'-CATGTGATGTGCCCTGATAT-3'. These mutations were respectively generated with these primer pairs: 5'-GACGAGGT TTTCTGTAGAC-3' (transversing wild-type TA-AG), 5'-AACCTGGAGGCAAAGTCACA-3' and 5'-TTGACTTT GCCCTCCAGTT-3' (transversing wild-type GT-CG), and the upstream primer and 5'-TCCCTAGGTAG CAGGTGCCAGAACATTT-3' and downstream reverse primer 5'-AGTG GTA-3' (transversing wild-type TG-CA), as displayed in Fig. 2B. The final PCR products contained KpnI and AvaII restriction sites, which were used to substitute the mutant PCR fragments into the same restriction sites in the wild-type G0S2 reporter construct. These mutants were DNA sequence confirmed. Promoter activities of these mutated RARE half-sites without (vehicle) and with RA (1 μM) were measured as above.

G0S2 polyclonal antibody. Full-length G0S2 cDNA was cloned into the pQE30 vector (Qiagen) to express His-tagged G0S2 polyclonal antibody as above.

G0S2 immunoblot analyses. Dose-dependent induction of G0S2 protein was studied using 5x105 NB4-S1 cells/ml treated without RA or with 10³, 10², and 10¹ nM RA dosages. Cells were harvested and lysed with radio-immunoprecipitation assay (RIPA) buffer (20 mM HEPES at pH 7.4, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, and 1X Protease Inhibitor). Total protein concentrations were determined with the Bio-Rad protein assay (Bio-Rad Laboratories, Inc., Hercules, CA) and SDS-PAGE and immunoblot analyses performed for detection of G0S2 and actin protein, respectively. RA induction of G0S2 protein was studied by culturing 1x10⁶ NB4-S1 cells with vehicle (DMSO), RA (10 nM) combined with or without the RAR pan-antagonist (10 nM or 100 nM, LGD100815) and the RXR agonist (100 nM, bexarotene) for 24 h before total protein isolation with RIPA buffer. Total protein was subjected to SDS-PAGE and immunoblot analysis for GOS2 and actin proteins, respectively. G0S2 protein half-life in NB4-S1 cells (5x10⁵ cells/ml) was studied by induction with RA (1 μM) overnight followed by addition of CHX (100 μg/ml final concentration). NB4-S1 cells were harvested thereafter at 0, 15, 30, 45 and 60 min for total protein isolation with RIPA buffer. Immunoblot analysis was performed to detect G0S2 expression.

RA induction of murine G0S2 protein. A previously described transgenic APL mouse model (26) was examined. In vivo mouse APL model experiments were performed according to a protocol reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Dartmouth College. Briefly, four female FVB mice (seven-weeks-old) were tail vein injected with 2x10⁶ APL donor cells. An RA pellet (10 mg, Innovative Research of America, Sarasota, FL) was implanted under the skin in two recipient mice on day 20, after receiving APL donor cell injections. Prior dosage titration of donor cells indicated recipient mice developed APL by day 20 after this injection. APL mice were sacrificed using IACUC approved procedures 24 h after RA-treatment. Spleens were removed and washed with cold PBS and these tissues were dispersed in cold PBS supplemented with 1X Protease Arrest protease inhibitor mixture and 5 mM EDTA and then filtered through a 40-μm nylon mesh to harvest cells from splenic tissues. The harvested cells were resuspended in 20 ml/ spleen, cold reticulocyte suspension buffer (10 mM Tris-HCl pH 7.5, 10 mM NaCl, and 3 mM MgCl₂) for 15 min on ice to lyse and thereby remove red blood cells. Cell suspensions were centrifuged, cell pellets were aliquoted and stored at -80°C. Total protein was isolated by resuspension of cell pellets in digitonin buffer (digitonin at 200 μg/ml, 250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl₂, 5 mM EDTA and 1X Protease arrest protease inhibitor mixture, at pH 7.5) for 30 min on ice. Immunoblot analyses were performed to detect G0S2 and actin proteins.

G0S2 expression in de novo APL cells. Fresh APL cells were collected under Institutional Review Board protocol approval and with informed consent, and, as previously described (27), density-gradient separated cells with 85% blasts were placed in short-term tissue culture in the presence of RA (1 μM) or vehicle (ethanol 1:1000). RNA was harvested after 24 h, and the differentiation response was assessed by the percentage of nitrotetrazolium blue (NBT) stained cells after 5 days. After cDNA synthesis, RT-PCR assays for G0S2 were performed using a primer set that generates a 269-bp PCR product. The quality of the RNAs and cDNA products was assessed by a competitive RT-PCR assay for GAPDH in which a known quantity of a mimic competitor was added to each assay (27).

Results

RA induction of G0S2 mRNA. Prior microarray analyses revealed G0S2 mRNA expression was increased following
RA-treatment of RA-sensitive NB4-S1 APL cells (14). The kinetics of RA mediated induction of G0S2 mRNA was determined in NB4-S1 cells using a semi-quantitative RT-PCR assay. G0S2 mRNA was robustly induced by RA (1 μM) treatment at 3 h and continued to increase up to 48 h (Fig. 1A). This induction did not depend on de novo protein synthesis since pre-treatment of NB4-S1 with CHX did not prevent G0S2 induction by RA-treatment (Fig. 1A). In contrast, CHX augmented RA effects on G0S2 mRNA induction from 3 to 12 h, as expected for a direct RA target gene (Fig. 1A). Treatment of NB4-S1 cells with actinomycin D (an inhibitor of RNA synthesis) revealed the G0S2 mRNA half-life was ~5.5 h (Fig. 1B). RA induction of G0S2 heteronuclear RNA was also sensitive to the inhibitor of RNA synthesis since actinomycin D blocked the immature G0S2 RNA product after only 1 h of treatment (Fig. 1C).

Transcriptional activation of the G0S2 promoter by RA-treatment. To determine the mechanistic basis for G0S2 mRNA induction by RA-treatment, co-transfection of G0S2 reporter assays were performed, as described in Materials and methods. Fig. 1D displays G0S2 promoter activity in the presence of RA-treatment without and with exogenous RARs via transient transfection. The G0S2 reporter construct (0.25 μg/μl), indicated RARs (0.15 μg/μl) and β-galactosidase expression vectors were co-transfected overnight into CHO cells. DMSO (vehicle) and RA (10 μM) were independently incubated with transfectants for 24 h before harvesting for reporter assays. The fold induction of G0S2 promoter activity increased over control by RA-treatment relative to vehicle-treated transfectants. Results were obtained from three independent experiments with error bars representing standard deviations.
(28) of the G0S2 promoter sequence revealed three RARE half-sites within this region (Fig. 2B). Mutation of each of these half-sites diminished RA activation of the G0S2 promoter, as shown in Fig. 2C.

RA-treatment induced G0S2 protein in NB4-S1 cells. Rabbit polyclonal antibody recognizing G0S2 protein was derived, as described in Materials and methods. This G0S2 antibody recognized a protein with the predicted G0S2 molecular weight of 11.3 kDa in RA-treated NB4-S1 cells, but not in untreated cells and in COS-1 cells expressing transfected myc-tagged G0S2 (Fig. 3A). Specificity of the anti-G0S2 antibody was confirmed when this protein was probed with an anti-myc antibody, which recognized the myc-epitope of the transfected tagged-G0S2 protein (Fig. 3A). As expected, G0S2 mRNA induction by RA-treatment occurred in RA-sensitive NB4-S1 cells and was accompanied by an increased G0S2 protein in a time- and dose-dependent manner while G0S2 protein was undetected in RA-resistant NB4-R1 cells (Figs. 1A and 3B and C). Prominent G0S2 induction in NB4-S1 cells was observed after only 10 nM of RA-treatment for 24 h (Fig. 3C). The half-life of G0S2 protein was ~15 min (Fig. 3D). Induction of G0S2 protein in NB4-S1 cells by RA-treatment was inhibited with an RAR pan-antagonist, LGD100815 (Fig. 3E). The RXR agonist, bexarotene, did not induce G0S2 protein expression in NB4-S1 cells (Fig. 3E).
Murine G0S2 protein induction by RA-treatment. To determine whether RA induced G0S2 in vivo, an established murine model of APL (26) was studied. As expected, RA-treatment significantly prolonged survival time of these APL mice [data not shown; 26]. Splenic enlargement was observed in the recipient mice 21 days after APL cell injection (data not shown).
after RA (1 μM)-treatment for 24 h or with ethanol (1:1000) vehicle control, as described in Materials and methods. G0S2 cDNA was amplified using competitive RT-PCR assays for mimic-GAPDH as an amplification control. NB4-S1 (NB4) mRNA was used as a positive control for RA induction of G0S2 mRNA. The differentiation responses of the APL patient-derived cells to RA-treatment are depicted by the percentage of nitrotetrazolium blue (NBT) positive cells following RA-treatment (Fig. 4B).

G0S2 mRNA induction by RA-treatment of cultured human APL cells. RA is an established differentiation therapy for APL (1,2). Whether RA induced G0S2 mRNA expression in cultures of APL cells isolated directly from patients was tested. APL cells from four cases exhibited elevated levels of G0S2 mRNA expression relative to vehicle controls when treated with RA (1 μM) for 24 h (Fig. 4B). The extent of G0S2 mRNA induction after RA-treatment varied between cases (Fig. 4B). Notably, RA-treatment induced a differentiation response, as demonstrated by prominent presence of NBT positive cells following RA-treatment, as displayed in Fig. 4A.

**Discussion**

G0S2 is a small, basic protein (11.3 kDa) with unknown functions that has potential sites for phosphorylation by protein kinase C and casein kinase II (18). Its promoter region has potential binding sites for the transcription factors AP1, AP2, AP3, and NFAT (18,19). In vivo and in vitro G0S2 mRNA induction by a PPAR agonist and the presence of a PPAR response element within the G0S2 promoter are each consistent with G0S2 functioning as a PPAR target gene (17). Microarray analyses of APL (14), RT-PCR assays of G0S2 from NB4-S1 cells treated with RA (Fig. 1A), studies of wild-type and mutant G0S2 promoter activity in response to RA-treatment (Figs. 1D and 2A and C) and bioinformatic analysis of the G0S2 promoter sequence (Fig. 2B) all indicate the G0S2 gene product is RA regulated in APL cells. RA induction of G0S2 mRNA progressively decreased after treatment with the RNA synthesis inhibitor actinomycin D (Fig. 1B). This indicated that RA induction of G0S2 was not due to RA stabilization of its mRNA. Induction of G0S2 mRNA by RA was tightly regulated with a half-life of 5.5 h (Fig. 1B). In contrast, G0S2 heteronuclear RNA was undetected after 1 h of treatment with this inhibitor of RNA synthesis, indicative of a rapid rate of post-transcriptional processing of heteronuclear G0S2 RNA to its mature mRNA (Fig. 2C).

RA induction of G0S2 expression was confirmed at the protein level. G0S2 protein expression increased as a function of time and RA dosage in NB4-S1 cells (Fig. 3B and C). RA was unable to augment G0S2 protein expression in RA-resistant NB4-R1 cells (Fig. 3B), as expected for an RA-target gene. This deregulation was caused by a mutation identified in the ligand binding domain of PML/RARα in NB4-R1 cells (29), which blocked G0S2 induction by RA (Fig. 3B). In addition, treatment of NB4-S1 cells with the RAR pan-antagonist LGD100815, inhibited RA mediated induction of G0S2 protein in a dose-dependent manner and an RXR ligand did not augment G0S2 protein expression (Fig. 3E). This result indicated G0S2 induction was RAR-dependent. G0S2 expression was modulated both at transcriptional (Fig. 1B and C) and post-translational levels with a protein half-life of only 15 min (Fig. 3D).

There was a likelihood that the anti-G0S2 antisera recognizing the human protein would recognize murine G0S2 since human G0S2 protein (gene bank accession no. M69199) has 78% amino acid homology with mouse G0S2 (gene bank accession no. NM_008059). Indeed, G0S2 protein was markedly elevated upon RA-treatment in murine splenic tissues of APL harboring mice (Fig. 4A). This result established RA induction of G0S2 protein *in vivo* in an APL murine model (Fig. 4A). The relevance of G0S2 induction by RA-treatment was extended to the clinical context. APL cells...
References

NIH T32-CA00959 (S.B.). E.D. is an American Cancer (NCI) grants RO1-CA087546 (E.D.), RO1-CA062275 (E.D.), Institutes of Health (NIH) and National Cancer Institute APL model. These studies were supported by the National APL donor cells and for his helpful consultation on use of this Biochemistry and Biophysics, UCSF for providing the murine The authors thank Dr Scott Kogan of the Department of
precise function of G0S2 in APL cell growth and differen-
tiation.

Acknowledgements

The authors thank Dr Scott Kogan of the Department of Biochemistry and Biophysics, UCSF for providing the murine APL model. These studies were supported by the National Institutes of Health (NIH) and National Cancer Institute (NCI) grants RO1-CA087546 (E.D.), RO1-CA062275 (E.D.), RO1-CA111422 (E.D.), RO1-CA56771 (R.G.), a Samuel Waxman Foundation Cancer Research Award (E.D.) and NIH T32-CA00959 (S.B.). E.D. is an American Cancer Society Clinical Research Professor.

References

1. Warrell RP Jr, Frankel SR, Miller WH Jr, et al: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-
19. Cristillo AD, Heximer SP, Russell L and Forsdyke DR: Cyclo-
21. Nason-Burchenal K, Maerz W, AlbANELLA J, Alloppena J, Martin P, Moore MAS and Dmitrovsky E: Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization. Differen-